PLXNB2 and glioblastoma: The inhibition of ANG with neomycin, a small molecule that prevents binding of ANG to its receptor, PLXNB2, decreased GBM growth in mice with platelet derived growth factor-induced GBM and a xenograft mouse model, demonstrating the potential of ANG inhibitors in GBM therapy (Yang et al., 2022).